title: A Retrospective Study of the Impact of Intraoperative Intact Parathyroid Hormone Monitoring During Total Parathyroidectomy for Secondary Hyperparathyroidism: STARD Study.
abstract: The study aimed to evaluate the diagnostic accuracy of intraoperative intact parathyroid hormone (IO-iPTH) in patients with secondary hyperparathyroidism (HPT). The cut-off for IO-iPTH monitoring remains unknown. This was a single-center retrospective review of 226 consecutive patients (107 males and 119 females) who underwent parathyroidectomy for secondary HPT between May 2010 and March 2014. The predetermined cut-off for IO-iPTH was a 70% IO-iPTH drop from baseline 10 minutes after total parathyroidectomy and thymectomy. We used <60 pg/mL iPTH value on postoperative day 1 (POD1) as an indicator of successful removal of parathyroid glands and reviewed the frequency of reoperation other than in autografted sites during the observation period. This study was based on the Standards for the Reporting of Diagnostic accuracy compliant. The reoperation rate in patients with >60 pg/mL iPTH value (POD1) was significantly higher than that in patients with <60 pg/mL iPTH value (POD1), (13.0% versus 0.5% P = 0.003). Sensitivity, specificity, and accuracy of >70% IO-iPTH drop were 97.5%, 52.2%, and 92.9%, respectively, this criterion was demonstrated to be beneficial in 26 patients. In 5 patients, <70% IO-iPTH drop was observed and further exploration enabled sufficient removal of parathyroid glands. In 21 patients, although fewer than 4 parathyroid glands were removed after enough explorations, >70% IO-iPTH drop enabled termination of operations and iPTH value (POD1) was <60 pg/mL.An iPTH value of <60 pg/mL (POD1) was a good predictor for successful parathyroidectomy. A 70% IO-iPTH drop from the baseline was appropriate to determine sufficient parathyroid gland removal during parathyroidectomy for patients with secondary HPT. [Corrected]
authors.affiliation: From the Department of Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital (TH, YT, MO, TY); and Department of Transplant Immunology, Nagoya University School of Medicine, Showa-ku, Nagoya, Aichi, Japan (TK).
authors.forename: Takahisa
authors.initials: T
authors.lastname: Hiramitsu
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tominaga
authors.forename: Manabu
authors.initials: M
authors.lastname: Okada
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Takaaki
authors.initials: T
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000601:surgery*; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D016343:Monitoring, Intraoperative / Q000379:methods* / Q000592:standards; D010281:Parathyroid Hormone / Q000378:metabolism*; D016105:Parathyroidectomy / Q000379:methods*; D012015:Reference Standards; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
chemical_list: D010281:Parathyroid Hormone; D002118:Calcium